ライフサイエンスコーパス: interferon

1 ing the production of IFNlambda4, a type III interferon.

2 chemokines KC and monokine induced by gamma interferon.

3 plex and regulated in part through antiviral interferons.

4 uction of both proinflammatory cytokines and interferons.

5 ts the expression of genes induced by type I interferons.

6 s and the major factors for the induction of interferons, a key component in vertebrate innate immuni

7 Here, we demonstrate that interferon-activated RNase L signaling blocks rotavirus

8 sphorylated RNA, and a signature of enhanced interferon activity in select tissues.

9 RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10)

10 Interferon alpha (IFN-alpha) and IFN-beta are type I IFN

11 had been demonstrated by others and us that interferon alpha (IFN-alpha) treatment of hepatocytes in

12 Serum levels of interferon alpha were significantly lower in patients wi

13 e both neuronal autoantibodies and levels of interferon alpha, two proposed causative agents in neuro

14 Interferon-alpha (IFN-alpha) can suppress production of

15 A third of patients receiving Interferon-alpha (IFN-alpha) treatment for Hepatitis-C d

16 Type I interferons, particularly interferon-alpha (IFN-alpha), play a vital role in the h

17 Interferon-alpha (IFNalpha), a type I interferon, is exp

18 eutics tyrosine kinase inhibitors (TKIs) and interferon-alpha (IFNalpha).

19 es in patients with COVID-19 showed a strong interferon-alpha response and an overall acute inflammat

20 EBV in low-grade LYG include treatment with interferon-alpha2b, whereas high-grade disease requires

21 0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rat

22 was characterized by enhanced expression of interferon and interferon-related genes.

23 wabs demonstrated that in addition to type-I interferon and interleukin-6-dependent inflammatory resp

24 ogical and biochemical parameters as well as interferon and nucleos(t)ide analogue treatment choice.

25 Anti-HCV therapy comprised pegylated interferon and ribavirin (PegIFN-RBV) plus one direct-ac

26 we identified those treated with a pegylated interferon and ribavirin regimen (PEG/RBV, n = 4764) or

27 response that predominantly involves type I interferons and interferon-related genes, whereas the WT

28 ting the transcriptional induction of type I interferons and other genes that collectively establish

29 generated viruses with inactive versions of interferon antagonist nonstructural protein 1 (nsp1), ns

30 This study highlights the role of viral interferon antagonists in shaping the kinetics and magni

31 Inactivation of these CoV interferon antagonists is a rational approach for genera

32 g PEDV with inactive versions of three viral interferon antagonists, nonstructural proteins 1, 15, an

33 suppress EBV reactivation.IMPORTANCE Type I interferons are important for controlling virus infectio

34 actions of R. parkeri with inflammasomes and interferons are similar to those of viruses, which can e

35 id DCs (pDCs), the major producers of type I interferon, are principally recognized as key mediators

36 ) of hepatitis C virus (HCV) screening found interferon-based antiviral therapy associated with incre

37 The effects of interferon-based therapies for hepatitis C virus (HCV) u

38 on CRISPR screen in cells prestimulated with interferon beta (IFN-beta), we identified a small number

39 lic dinucleotide activation of STING induces interferon beta expression to initiate innate immune def

40 six drugs (remdesivir, lopinavir-ritonavir, interferon beta, corticosteroids, chloroquine and hydrox

41 Treatment of CS-exposed ALI cultures with interferon beta-1 abrogated the viral infection, suggest

42 y and comparable safety of fingolimod versus interferon beta-1a (IFN beta-1a) in paediatric-onset mul

43 ta 1, TIR-domain containing adapter inducing interferon-beta (TRIF), TRIF-related adaptor molecule, i

44 Previously, this vector was used for interferon-beta gene transfer in mouse models of melanom

45 umab, rituximab, ocrelizumab) or injectable (interferon-beta, glatiramer acetate) DMTs.

46 feron suppression, and viral infection under interferon-competent conditions.

47 Moreover, we show that type I interferons do not control SARS-CoV-2 replication in viv

48 pared our data to previous findings from the interferon era.

49 long-lasting immune stimulation in terms of interferon expression at the injection site and in drain

50 PARP reduced viral replication and increased interferon expression, suggesting that TiPARP functions

51 ccinated infants had increased production of interferon gamma (IFN-gamma) and monokine induced by gam

52 and evaluated CAR-T cell activation through interferon gamma (IFN-gamma) production and CD107a membr

53 The mice were treated with interferon gamma (IFNgamma) intraperitoneally for 3 d or

54 t manner, which was enhanced by priming with interferon gamma (IFNgamma).

55 ding ICAM-1, VCAM-1, HLA class I and II, and interferon gamma receptor.

56 Studies comparing the performance of interferon gamma release assays (IGRAs) and the tubercul

57 By comparison, peripheral blood interferon gamma release assays in the same cohort achie

58 Interferon gamma was shown to contribute to the host inf

59 titers and median frequencies of F-specific interferon gamma-secreting T cells also increased substa

60 MVA-NP+M1 activated a marked interferon gamma-secreting T-cell response to M1 peptide

61 The median frequency of RSV-F-specific interferon gamma-secreting T-cells after a ChAd155-RSV h

62 The natural history of anti-interferon-gamma (IFN-gamma) autoantibody-associated imm

63 We find that T cell infiltration and interferon-gamma (IFN-gamma) signaling signatures corres

64 We also demonstrate a role for the cytokine interferon-gamma (IFNgamma) and the enzyme transglutamin

65 d by high levels of infiltrating T cells and interferon-gamma (IFNgamma) signalling, improves the res

66 reduced secretion of interleukin-2 (IL2) and interferon-gamma (IFNgamma), two factors critical for T

67 r maintaining cell fitness after exposure to interferon-gamma (IFNgamma).

68 Frequencies of interferon-gamma +CD4+T cells expressing CD38, HLADR, an

69 Rather, elimination of type I cytokine interferon-gamma activity enhanced insulin sensitivity i

70 -1beta (IL-1beta), IL-6, IL-8, IL-10, IL-17, interferon-gamma and differential T and B cell subset ly

71 icacy and safety of emapalumab (a human anti-interferon-gamma antibody), administered with dexamethas

72 afin improved leptin sensitivity via reduced interferon-gamma expression and induced adipose leptin e

73 hrough the rapid synthesis of a glycosylated interferon-gamma fragment and the chemokine-binding prot

74 ction of higher (p < 0.01) concentrations of interferon-gamma in plasma of low responders compared to

75 Furthermore, ex vivo stimulation with interferon-gamma induced endogenous PD-L1 expression and

76 response characterized by the production of interferon-gamma is needed.

77 Interferon-gamma levels of endotoxin-stimulated PBMCs fr

78 Interleukin-1b and interferon-gamma levels were upregulated in skin of allo

79 AK-STAT, immune deficiency and cross-species interferon-gamma pathways, have advanced our understandi

80 e, spike, and nucleocapsid peptides elicited interferon-gamma production, in 27 (59%), 12 (26%), and

81 investigated feasibility and accuracy of an interferon-gamma release assay (IGRA) for detection of T

82 Interferon-gamma was produced by a large fraction of RBD

83 m levels of tumor necrosis factor -alpha and interferon-gamma were significantly increased in the CSD

84 Tax(+) and Tax(+)/interferon-gamma(-/-) malignancies of the ear, tail, and

85 nd neutralizing) and CD4+ T-cell (expressing interferon-gamma, interleukin-2, and CD40 ligand) respon

86 12 induced sustained intratumoural levels of interferon-gamma, substantially reduced its systemic lev

87 vere disease) and 16 unexposed donors, using interferon-gamma-based assays with peptides spanning SAR

88 D11c(+) macrophage) M1-like polarization and interferon-gamma-expressing T-helper type 1 (Th1) cells

89 inally identified as a receptor expressed on interferon-gamma-producing CD4(+) and CD8(+) T cells.

90 n of interleukin-4 and reduced production of interferon-gamma.

91 pression of IRF8 that was further induced by interferon-gamma.

92 ine monophosphate (cGAMP), an agonist of the interferon gene inducer STING (stimulator of interferon

93 Although we observed an interferon gene signature in addition to downregulated n

94 he stimulator of the cyclic GMP-AMP synthase interferon genes (cGAS-STING) innate immune pathway.

95 (DDR), cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway activation, and an

96 ed the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway by using two appro

97 antiviral responses, including stimulator of interferon genes (STING) activation.

98 gments and then activating the stimulator of interferon genes (STING) cytosolic DNA-sensing pathway a

99 hat promote lysosomal-mediated stimulator of interferon genes (STING) degradation.

100 Stimulator of interferon genes (STING) is a receptor in human cells th

101 signaling mediated by the cGAS-stimulator of interferon genes (STING) pathway in patient-derived fibr

102 The Stimulator of Interferon Genes (STING) pathway initiates potent immune

103 The stimulator of interferon genes (STING) pathway plays an important role

104 MP), which binds and activates stimulator of interferon genes (STING).

105 rs cyclic GMP-AMP synthase and stimulator of interferon genes in wild-type (WT) mice.

106 Hepatitis C virus SVR decreased monocyte interferon genes MX1, IFI27, and CD169 in coinfection an

107 STING (STimulator of INterferon Genes) mediates protective cellular response

108 lic DNA sensing adaptor STING (stimulator of interferon genes) play a critical role in vascular infla

109 interferon gene inducer STING (stimulator of interferon genes).

110 ough the inhibition of RB1 and stimulator-of-interferon-genes (STING) to propagate cells with a high

111 Type I interferons have a crucial role in the progression to es

112 tivates the host cytosolic DNA sensing STING/interferon I pathway, resulting in enhanced cross-primin

113 ion, mediated by CD8 T cell-intrinsic type I interferon (IFN) and signal transducer and activator of

114 Type I interferon (IFN) antiviral responses and SARS-CoV-2-spec

115 ia, and we have shown previously that type I interferon (IFN) contributes to the pathogenesis of this

116 Type I interferon (IFN) drives pathology in systemic lupus eryt

117 ACE2 has recently been proposed to be interferon (IFN) inducible, suggesting that SARS-CoV-2 m

118 Type I interferon (IFN) is a major output of STING signaling; h

119 2'3'cGMP-AMP (cGAMP), which in turn triggers interferon (IFN) production via the STING pathway.

120 TLR7-mediated disease, which requires type I interferon (IFN) receptor signaling, TLR9-driven fatalit

121 JUNV and MACV infections stimulate a robust interferon (IFN) response in a retinoic acid-inducible g

122 Type I interferon (IFN) response is commonly recognized as the

123 also increased early infectivity and type I interferon (IFN) responses in mouse bone marrow-derived

124 signaling (MAVS) protein-dependent antiviral interferon (IFN) responses.

125 Here, we report that interferon (IFN) signals convey resistance to CDC-induce

126 adults with ARDS have elevated expression of interferon (IFN) stimulated genes (ISGs) associated with

127 halitis in the Western world, and the type I interferon (IFN) system is important for antiviral contr

128 t cells secreted increased amounts of type I interferon (IFN), which could be limited by CGAS or STIN

129 S vasculopathy had antibody that neutralized interferon (IFN)-alpha, but not IFN-gamma.

130 cytokine polarization pattern that included interferon (IFN)-gamma and interleukin (IL)-13.

131 myeloid differentiation primary response 88, interferon (IFN)-gamma, interleukin (IL)1-beta, tumor ne

132 tabilize USP18, a potent inhibitor of type I interferon (IFN)-I.

133 cinia virus, and Zika virus through a type I interferon (IFN)-independent mechanism.

134 tor transporter protein 4 (RTP4) as a potent interferon (IFN)-inducible inhibitor of human pathogens

135 Interferon (IFN)-Is are crucial mediators of antiviral i

136 es of COVID-19 lungs, including emergence of interferon (IFN)-mediated inflammatory responses, loss o

137 We identified a predominant type III interferon (IFN)-mediated innate response to HuNoV infec

138 Correspondingly, the expression of interferon (IFN)-responsive genes (IRGs) in cells and in

139 x of plasmacytoid dendritic cells (pDCs), an Interferon (IFN)-responsive macrophage population, and a

140 ional modeling to investigate how the type I interferon (IFN)-responsive regulatory network operates

141 s by mammalian reovirus requires both type I interferon (IFN)-signaling and viral replication events

142 Cs) and blunts systemic production of type I interferon (IFN).

143 Alpha/beta interferon (IFN-alpha/beta) signaling through the IFN-al

144 response that included high levels of gamma interferon (IFN-gamma) and tumor necrosis factor alpha (

145 Furthermore, genetic deletion of gamma interferon (IFN-gamma) but not IL-22 or antibody-mediate

146 g plasmacytoid dendritic cells-(pDCs)-Type I interferon (IFN-I) and acts as autoantigen for pathogeni

147 cytoid dendritic cells (pDCs) produce type I interferon (IFN-I) and are traditionally defined as bein

148 imuli by inhibiting the NF-kappaB and type I interferon (IFN-I) pathways.

149 lation of IRF3 (not TBK1) and enhance type I interferon (IFN-I) production in macrophages.

150 Type I interferon (IFN-I) provides effective antiviral immunity

151 In this report, we evaluate type I interferon (IFN-I) sensitivity of SARS-CoV-2 relative to

152 depends on Mtb-induced production of type I interferon (IFN-I).

153 ting capacity through activation of a type I interferon (IFN-I)/STAT1 pathway when caspases are inhib

154 s HSCs in the bone marrow (BM) via a type II interferon (IFN-II) or interleukin-1 (IL1) response, res

155 s, characterized by the production of type-I interferons (IFN) including IFNbeta.

156 s cytokines and chemokines, including type I interferons (IFN-I).

157 ction resulted in the expression of type III interferons (IFN-lambda).

158 4; infliximab, n = 101; adalimumab, n = 153; interferon [IFN]-beta-1a intramuscularly [IM], n = 38; I

159 regulation of the IFNAR1 chain of the type I interferon (IFN1) receptor.

160 to intracellular dsRNA by expressing type I interferons (IFNs) and inducing apoptosis, but that they

161 s ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for the

162 Interferons (IFNs) are widely used in treating coronavir

163 Type I, II, and III interferons (IFNs), which all signal via the STAT1 trans

164 y repressing STAT1/2 and secretion of Type I Interferons (IFNs).

165 tor with many target genes, including type I interferons (IFNs).

166 osphorylated, leading to induction of type I interferons (IFNs).

167 enotype accompanying inborn errors of type I interferon immunity.

168 of antiviral effectors in response to type I interferons.IMPORTANCE Viral infection triggers the secr

169 Basal levels of type I interferon in the long-term infected bat cells were high

170 eptidase 4 (DPP4) and higher basal levels of interferon in these cells.

171 tly higher expression of both type I and III interferons in IPEC-DQ cells than the parental rPEDV.

172 owed that BST-2 is a major determinant of an interferon-induced block of ASLV release.

173 ammatory environment, characterized by serum interferon-induced protein 10 and interleukin 1alpha, is

174 sed to study the antiviral activity of IFIT (interferon-induced protein with tetratricopeptide repeat

175 d time = 6.3 days) demonstrated reduction in interferon-induced transcription, recovery of transcript

176 and higher ICAM1, VE-cadherin, occludin and interferon-induced transmembrane protein mRNAs compared

177 virus transcription, and contributes to the interferon-induced upregulation of known restriction fac

178 Thus, interferon-induced variability in ACE2 expression levels

179 oamy macrophages are not proinflammatory but interferon-inducible cell and inflammatory macrophages a

180 CXC-chemokine ligand 9 (CXCL9) is an interferon-inducible chemokine of the CXC family and is

181 adenylate synthetases (OASs) are a family of interferon-inducible enzymes that require double-strande

182 strin homology (PH) domains 2 (ADAP2), gamma-interferon-inducible lysosome/endosome-localized thiolre

183 In those with SVR, interferon-inducible protein 10, ATX, and Mac2BP levels

184 The interferon-inducible transmembrane (IFITM) proteins belo

185 y protein, endoplasmic reticulum-associated, interferon-inducible) to enhance viral infectivity.

186 The enhanced interferon-inducing phenotypes were linked to either a d

187 Interferon is found to affect both haematopoietic and me

188 Interferon-alpha (IFNalpha), a type I interferon, is expressed in the islets of type 1 diabeti

189 e is defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high e

190 The interferon lambda 4 gene (IFNL4) regulates immune respon

191 Finally, we show that the clinical candidate interferon-lambda1a (IFN-lambda1a) potently inhibits SAR

192 The absence of USP18 results in unmitigated interferon-mediated inflammation and is lethal during th

193 urring picornavirus that induced a canonical interferon-mediated response and hundreds of antiviral d

194 protein that functions during NF-kappaB- and interferon-mediated signaling in response to extracellul

195 ma (IFN-gamma) and monokine induced by gamma interferon (MIG) (CXCL9) in response to mycobacterial st

196 in G (IgG) autoantibodies (auto-Abs) against interferon-omega (IFN-omega) (13 patients), against the

197 Type I interferons, particularly interferon-alpha (IFN-alpha),

198 E clinical endophenotypes, with genes of the interferon pathway being highly enriched in DCEs that be

199 High viral cases have high activation of interferon pathway genes and a predominant M1-like macro

200 : Sofosbuvir (SOF)/ribavirin (RBV)/pegylated interferon (PEG-IFN), 25.2%; SOF/RBV, 62.4%; SOF/RBV/dac

201 ent for children aged <12 years is pegylated interferon plus ribavirin.

202 and positive immune score as a surrogate of interferon-primed exhausted CD8 + T-cells in the tumor m

203 of characteristic biomarkers (type I and III interferons) produced by PBMCs transfected with NANPs.

204 Gamma interferon-producing cells peaked at day 24 postimmuniza

205 pe I interferon-regulated genes due to lower interferon production and responsiveness, blunted STAT1

206 ) protein, which limits RIG-I activation and interferon production by the infected cell.

207 acytoid dendritic cells, are responsible for interferon production prior to clinical autoimmunity.

208 nate RNA sensing with signaling response and interferon production remains unclear.

209 ts into autophagosomes, and IRF3 activation, interferon production, and antiviral activity are compro

210 G translocates to endosomes for induction of interferon production, while an alternate trafficking ro

211 e gene I (RIG-I), thereby stimulating type I interferon production.

212 uate the effect of ribavirin and recombinant interferon (RBV/rIFN) therapy on the outcomes of critica

213 ministrated using different routes in type-I interferon receptor deficient A129 mice.

214 cell-intrinsic Toll-like receptor and type 1 interferon receptor signaling, upregulated an IRF8-depen

215 e includes suppression of hundreds of type I interferon-regulated genes due to lower interferon produ

216 al deficiency of antiviral tumor-suppressive interferon regulatory factor 1 (IRF-1) selectively promo

217 effect is mediated in large part by the gene interferon regulatory factor 1.

218 -beta (TRIF), TRIF-related adaptor molecule, interferon regulatory factor 3 (IRF-3), receptor-interac

219 Interferon regulatory factor 3 (IRF3) and IRF7 are close

220 e via the restoration of host immunity in an interferon regulatory factor 3-dependent manner.

221 revious study found microglial expression of interferon regulatory factor 5 (IRF5) and IRF4 was relat

222 Interferon regulatory factor 7 (IRF-7) is a transcriptio

223 , thus preventing association of hSTAT2 with interferon regulatory factor 9.

224 The restrictive effects of IFN-I require the interferon regulatory factor IRF5, which upregulates gen

225 h these receptors stimulates, in most cases, interferon regulatory factor-dependent type I IFN synthe

226 man herpesvirus 8 (HHV-8) encodes four viral interferon regulatory factors (vIRFs 1 to 4), all of whi

227 redominantly involves type I interferons and interferon-related genes, whereas the WT and DUBmut viru

228 zed by enhanced expression of interferon and interferon-related genes.

229 ve capacity (p = 0.0005) and are more type I interferon-resistant (p = 0.007) than those transmitted

230 tified as negative regulators of the type-II interferon response (for example, Ptpn2, Socs1 and Adar1

231 defective negative regulation of the type I interferon response can lead to autoinflammation.

232 Women have a more robust type 1 interferon response during HIV infection relative to men

233 Here, we found that ROS impaired interferon response during murine herpesvirus infection

234 onexpressing mice, but enrichment for type I interferon response gene changes was specifically observ

235 e identified inverse expression of antiviral interferon response genes (ISGs) and positive correlatio

236 ted with ICB resistance, including increased interferon response genes and glucocorticoid response ge

237 orresponds to distinct spatial expression of interferon response genes demonstrating the intra-pulmon

238 oc analysis, rucaparib induced expression of interferon response genes in HR-deficient cancers.

239 protect virus-infected cells from the type I interferon response in cells undergoing lytic virus repl

240 h nucleic acids triggers an antiviral type I interferon response in neuroglia, resulting in complemen

241 tive to uninfected cells, and disrupting the interferon response in persistently infected bat cells i

242 broad clonal T cell expansion and curtailed interferon response in severe compared with mild Neuro-C

243 tial cellular functions acts to suppress the interferon response to viral infection.

244 In contrast, no RT-dependent interferon response was detected following transduction

245 ather than uniquely to antagonize the type I interferon response.

246 c cells within tumors and triggered a type I interferon response.

247 icPEDV-mut4 elicited robust interferon responses and was severely impaired for repli

248 orrelate with the ability to induce elevated interferon responses in the vaccinated hosts.

249 these viruses and produced higher levels of interferon responses than were seen with wild-type icPED

250 Expression of interferon-responsive genes, including ACE2, increased a

251 Interferon-responsive PK1 cells were infected with these

252 ient in an adaptor molecule, STAT1(-/-), for interferon signaling had 46,000 copies/mug RNA.

253 e monophosphate synthase (cGAS) and enhanced interferon signaling mediated by the cGAS-stimulator of

254 , including molecules involved in the type I interferon signaling pathway and caspase-6.

255 ent protein binds to a protein in the type I interferon signaling pathway Tyk2 and inhibits the expre

256 fection impaired AM crawling via the type II interferon signaling pathway, and this greatly increased

257 Besides finding key components of the interferon signaling pathway, we discovered a new restri

258 In addition to known components of the interferon signaling pathway, we found that replication

259 an enrichment in the IL-12 family and type I interferon signaling pathways was observed among the set

260 pharmacologically inhibiting necroptosis or interferon signaling protects human organoids derived fr

261 unctuated by a late prenatal spike in type I interferon signaling that promotes perinatal HPC expansi

262 ted cells, EBOV downregulates STAT1 mRNA and interferon signaling, and it upregulates putative pro-vi

263 clear factor-kappaB-dependent, type I and II interferon signaling, and leukocyte activation pathways.

264 to the human disease, such as type I and II interferon signaling, cell-cell adhesion, leukocyte chem

265 in a Dectin-1 and Card9- and type I and III interferon signaling-dependent manner, respectively.

266 DCs, NP-R848-PUUC induced both NF-kappaB and interferon signaling.

267 cytosolic DNA-sensing pathway and downstream interferon signaling.

268 ic cells type 2 (cDC2) due to reduced type 1 interferon signalling.

269 ndependent of disease activity and the blood interferon signature.

270 h was associated with an aberrant epithelial interferon signature.

271 ro-COVID CSF leukocytes featured an enriched interferon signature; however, this was less pronounced

272 Upregulation of interferon stimulated genes precedes these defects, whic

273 y, mediated by the expression of an array of interferon-stimulated antiviral genes, is a vital part o

274 heral blood mononuclear cells and quantified interferon-stimulated gene (ISG) expression in CD4 T cel

275 rikingly, we discovered that ACE2 is a human interferon-stimulated gene (ISG) in vitro using airway e

276 ACE2 has been proposed as an interferon-stimulated gene (ISG).

277 IFN synthesis followed by JAK/STAT-dependent interferon-stimulated gene expression.

278 ses green fluorescent protein (GFP) under an interferon-stimulated gene promoter, we repeatedly obser

279 a high-throughput genetic screen of a human interferon-stimulated gene short-hairpin RNA library, we

280 n CHB patients, peg-IFN treatment induced an interferon-stimulated gene signature in monocytes and in

281 is a processing body (P-body) protein and an interferon-stimulated gene that can affect replication o

282 Cholesterol 25-hydroxylase (CH25H) is an interferon-stimulated gene that converts cholesterol to

283 preciated individual- and cell-type-specific interferon-stimulated gene upregulation, we describe tem

284 One of these, IFIT2, is an interferon-stimulated gene with well-established antivir

285 n in hBMECs and inhibit the transcription of interferon-stimulated genes (ISG).

286 Here, we screen a library of nearly 400 interferon-stimulated genes (ISGs) against a biologicall

287 nd primary fibroblasts leads to induction of interferon-stimulated genes (ISGs) through JAK/STAT sign

288 Here, we report that one of the interferon-stimulated genes (ISGs), cholesterol 25-hydro

289 7 days post infection, with no induction of interferon-stimulated genes after 3 days.

290 l antiviral cytokine, IFNB1, and a subset of interferon-stimulated genes.

291 RABV and facilitates the production of some interferon-stimulated genes.

292 in common by type I and III IFNs have strong interferon-stimulated response element (ISRE) promoter m

293 promised NS5-mediated hSTAT2 degradation and interferon suppression, and viral infection under interf

294 The interferon system is the first line of defense against v

295 -AMP, which mediates the induction of type I interferons through the STING-TBK1-IRF3 signalling axis(

296 wing of TCR repertoires were associated with interferon type I and III responses, early CD4(+) and CD

297 ctive effect in engineered cartilage against interferon type II.

298 tory cytokines, but the production of type I interferons, which are key antiviral mediators, is repor

299 l infection triggers the secretion of type I interferons, which in turn induce the expression of hund

300 the infection and respond by inducing type I interferons, which limits virus replication.